# mRNA-1010

Type: Product

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/mrna-1010
Canonical HTML page: https://getbiobrief.com/entity/mrna-1010

## Timeline

- **2026-Q4**: Anticipated PDUFA — Expected deadline for the FDA's final approval decision.
- **2026-02-18**: FDA U-Turn — FDA agrees to review the application after resolving the public dispute.
- **2026-02-18**: Regulatory Reversal — FDA agrees to review the application after Moderna addresses concerns.
- **2026-02-10**: Political Controversy — Reports emerge that the vaccine chief overruled career scientists to block the shot.
- **2026-01-10**: Refusal to File — FDA issues a shocking rejection of the application, sparking a public dispute.
- **2026-01**: Refusal to File — FDA issues an RTF citing deficiencies in the initial application.
- **2025-11-15**: Initial BLA Submission — Moderna submits its Biologics License Application for mRNA-1010.
- **2025-Q4**: BLA Submission — Moderna submits Biologics License Application for mRNA-1010.

## Recent coverage (2 stories)

### FDA Reverses Course, Agrees to Review Moderna’s mRNA Flu Vaccine
2026-02-19 00:58:25 · Sentiment: Positive · Impact: 7/10 · Sources: 2

The FDA has rescinded its initial refusal to file Moderna’s Biologics License Application for its seasonal flu vaccine, mRNA-1010. This rare regulatory pivot clears the path for a formal review of the first mRNA-based influenza shot, a critical milestone for Moderna’s post-pandemic growth strategy.
Full story: https://getbiobrief.com/story/fda-reverses-moderna-flu-vaccine-review

### FDA Reverses Course on Moderna mRNA Flu Shot After Political Dispute
2026-02-18 18:51:48 · Sentiment: Positive · Impact: 8/10 · Sources: 6

Moderna has confirmed that the FDA will officially review its mRNA-based influenza vaccine following a highly publicized regulatory standoff. The reversal comes after reports that the Trump administration's vaccine leadership initially overruled career scientists to block the application.
Full story: https://getbiobrief.com/story/fda-reverses-moderna-flu-shot-review

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.